US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gene Editing

372.94

+4.901.33%

Number of Gainers:3

Number of Losers:2

Number of Flat:- -

PE:- -

High:383.86

Open:367.33

Low:354.48

Close:368.04

Loading ...

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and Pharvaris (PHVS)

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

Crispr Therapeutics AG (CRSP) Gets a Hold from Barclays

Crispr posts strong CTX310 data, says Chardan

CRISPR Therapeutics Advances Phase 1 Trials for Cardiovascular Disease Programs

MT Newswires Live

Crispr Therapeutics Reports Positive Additional Phase 1 Data For Ctx310™ Targeting Angptl3 And Provides Update On In Vivo Cardiovascular Pipeline

Sangamo Biosciences (SGMO) Receives a Buy from H.C. Wainwright

Sangamo Therapeutics Says Phase 1/2 Fabry Disease Study Showed Favorable Safety Profile; Shares Up Pre-Bell

MT Newswires Live

BRIEF-Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

Sangamo Therapeutics Receives Key FDA Designations and Advances Towards 2026 BLA Submission for Fabry Disease Gene Therapy

Sangamo Therapeutics Inc - to Submit Bla in 2026

THOMSON REUTERS

Sangamo Therapeutics Inc - Isaralgagene Civaparvovec Shows Favorable Safety and Tolerability Profile

THOMSON REUTERS

Sangamo Therapeutics Inc - STAAR Study Shows Positive Mean Annualized Egfr Slope at 52 Weeks

THOMSON REUTERS

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

THOMSON REUTERS

The Best Stocks to Invest $1,000 in Right Now

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

Crispr Therapeutics AG (CRSP) Gets a Hold from Bernstein

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":372.94043,"timestamp":1751399999999,"preClose":368.03903,"halted":0,"volume":15816522,"delay":0,"changeRate":0.013318,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":4.901398,"latestTime":"07-01 16:00:00 EDT","open":367.33228,"high":383.86002,"low":354.47617,"amount":254427196.46494,"amplitude":0.079839,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751443200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":1.922474,"peRate":-4.482417,"turnoverRate":0.026947,"increases":3,"decrements":2,"flats":0,"marketCap":7291426352,"floatMarketCap":7047751552},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":383.86002,"amplitude":0.079839,"preClose":368.03903,"low":354.47617,"pbRate":"1.922474","latestPrice":372.94043,"volume":15816522,"delay":0,"open":367.33228,"prevYearClose":376.62552,"prevWeekClose":363.1704,"prevMonthClose":368.039,"prevQuarterClose":368.039,"fiveDayClose":361.3764,"twentyDayClose":297.7491,"sixtyDayClose":277.284,"secType":"PLATE","market":"US","turnoverRate":0.026947,"peRate":-4.482417,"marketCap":7291426352,"floatMarketCap":7047751552,"timestamp":1751399999999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":3,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2547944550","title":"Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and Pharvaris (PHVS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2547944550","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547944550?lang=en_us&edition=fundamental","pubTime":"2025-06-30 20:30","pubTimestamp":1751286628,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Crispr Therapeutics AG (CRSP – Research Report), G...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-crispr-therapeutics-ag-crsp-galapagos-glpg-and-pharvaris-phvs-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-crispr-therapeutics-ag-crsp-galapagos-glpg-and-pharvaris-phvs-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","GLPG","LU1861559042.SGD","BK4588","HCSG","BK4139","BK4137","BK4585","BK4556","CRSP","BK4007","LU1861558580.USD","BK4210","PHVS","AG"],"gpt_icon":0},{"id":"2546724774","title":"Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2546724774","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546724774?lang=en_us&edition=fundamental","pubTime":"2025-06-28 17:04","pubTimestamp":1751101440,"startTime":"0","endTime":"0","summary":"Editas Medicine stock has more than doubled over the past few months, but it's still way down from its previous peak.Investors looking for stocks that can produce dramatic gains in a short amount of time will want to turn their heads toward the biopharmaceutical space. Chasing short-term gains isn't the smartest way to invest, but hardly a month goes by without at least one stock from this industry shooting through the roof as the drugs it develops cross important milestones.The average Wall Street analyst following Editas Medicine  thinks the gene therapy stock can reach $3.25 per share in the next year. From recent prices, this implies a gain of about 53% over the next 12 months.Shares of Editas Medicine have more than doubled since briefly falling below $1 per share in April. Before rushing out to buy the stock in hopes it can surpass analysts' estimates and double investors' money again, you should know the stock has fallen more than 97% from the peak it set in 2021. What can inves","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/28/wall-street-expects-editas-medicine-to-soar-53-is/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["CRSP","LU1861559042.SGD","EDIT","LU1861558580.USD","BK4588","BK4611","BK4556","BK4139","BK4585"],"gpt_icon":0},{"id":"2546537027","title":"Crispr Therapeutics AG (CRSP) Gets a Hold from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2546537027","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546537027?lang=en_us&edition=fundamental","pubTime":"2025-06-27 01:46","pubTimestamp":1750959966,"startTime":"0","endTime":"0","summary":"In a report released today, Gena Wang from Barclays reiterated a Hold rating on Crispr Therapeutics AG (CRSP – Research Report), with a price targe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-gets-a-hold-from-barclays-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-gets-a-hold-from-barclays-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4585","BK4588","LU1861559042.SGD","BK4210","CRSP","BK4139","AG","BK4611","LU1861558580.USD"],"gpt_icon":0},{"id":"2546734736","title":"Crispr posts strong CTX310 data, says Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2546734736","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546734736?lang=en_us&edition=fundamental","pubTime":"2025-06-26 22:35","pubTimestamp":1750948522,"startTime":"0","endTime":"0","summary":"Crispr Therapeutics (CRSP) reported encouraging updated Phase I data for its in vivo liver editing candidate CTX310, showing up to 82% reduction in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-posts-strong-ctx310-data-says-chardan-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-posts-strong-ctx310-data-says-chardan-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","BK4139","CRSP","BK4611","LU1861559042.SGD","BK4556","BK4585","BK4588"],"gpt_icon":0},{"id":"2546787945","title":"CRISPR Therapeutics Advances Phase 1 Trials for Cardiovascular Disease Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2546787945","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546787945?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:42","pubTimestamp":1750938165,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics  said Thursday that new phase 1 clinical data for its treatment CTX310 continues to demonstrate dose-dependent reductions in triglycerides and low-density lipoprotein, which are recognized risk factors for atherosclerotic heart disease.The data showed peak reduction of up to 82% in triglycerides and up to 86% in low-density lipoprotein, with a well-tolerated safety profile, the company said.CRISPR said it expects to present complete phase 1 data of CTX310, which targets the ANGPTL3 gene, at a medical meeting in H2.The company said it also expects an update for its phase 1 trial of CTX320 in H1 2026. The investigational treatment targets the LPA gene in patients with elevated lipoprotein, a genetically determined risk factor associated with increased incidence of major adverse cardiovascular events.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","LU1861559042.SGD","BK4585","LU1861558580.USD","BK4556","CRSP","LENZ","BK4082","BK4588","CSII","BK4611","BK4139"],"gpt_icon":0},{"id":"2546478267","title":"Crispr Therapeutics Reports Positive Additional Phase 1 Data For Ctx310™ Targeting Angptl3 And Provides Update On In Vivo Cardiovascular Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2546478267","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546478267?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:15","pubTimestamp":1750936556,"startTime":"0","endTime":"0","summary":"June 26 (Reuters) - CRISPR Therapeutics AG ::*CRISPR THERAPEUTICS REPORTS POSITIVE ADDITIONAL PHASE 1 DATA FOR CTX310 TARGETING ANGPTL3 AND PROVIDES UPDATE ON IN VIVO CARDIOVASCULAR PIPELINE*CRISPR TH","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nRSD63fZ5v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Crispr Therapeutics Reports Positive Additional Phase 1 Data For Ctx310™ Targeting Angptl3 And Provides Update On In Vivo Cardiovascular Pipeline","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","BK4139","BK4588","BK4611","BK4585","CRSP","LU1861558580.USD","BK4556"],"gpt_icon":0},{"id":"2546234723","title":"Sangamo Biosciences (SGMO) Receives a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2546234723","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546234723?lang=en_us&edition=fundamental","pubTime":"2025-06-25 00:35","pubTimestamp":1750782917,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of $1...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/sangamo-biosciences-sgmo-receives-a-buy-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/sangamo-biosciences-sgmo-receives-a-buy-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4139","SGMO"],"gpt_icon":0},{"id":"2545717280","title":"Sangamo Therapeutics Says Phase 1/2 Fabry Disease Study Showed Favorable Safety Profile; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2545717280","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545717280?lang=en_us&edition=fundamental","pubTime":"2025-06-24 21:26","pubTimestamp":1750771575,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics  shares were up premarket Tuesday after the company reported topline results from a phase 1/2 study evaluating ST-920 for the treatment of Fabry disease and said the gene therapy candidate showed a favorable safety and tolerability profile.Following a single dose, ST-920 demonstrated a \"positive\" mean annualized estimated glomerular filtration rate, or eGFR, slope at 52-weeks across all dosed patients, the company said.Sangamo said that the Food and Drug Administration agreed that the eGFR slope would serve as an intermediate clinical endpoint under an accelerated approval pathway. GeFR is a key indicator of kidney function decline.Looking ahead, the genomic medicine company said it intends to submit a biologics license application under an accelerated approval pathway as early as Q1 2026.Shares of the company were 6% higher ahead of Tuesday's opening bell.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SGMO","BK4556","BK4539","BK4007","BK4139"],"gpt_icon":0},{"id":"2545828372","title":"BRIEF-Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2545828372","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545828372?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:12","pubTimestamp":1750767139,"startTime":"0","endTime":"0","summary":"BRIEF-Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry DiseaseJune 24 (Reuters) - Sangamo Therapeutics Inc SGMO.O:SANGAMO THERAPEUTICS ANNOUNCES POSITIV","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABNQZ71:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMO","BK4556"],"gpt_icon":0},{"id":"2545794284","title":"Sangamo Therapeutics Receives Key FDA Designations and Advances Towards 2026 BLA Submission for Fabry Disease Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2545794284","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545794284?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:05","pubTimestamp":1750766723,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics Inc., a genomic medicine company, has announced that its investigational gene therapy, isaralgagene civaparvovec, has received significant regulatory designations from various health authorities. The U.S. Food and Drug Administration  has granted the therapy Orphan Drug, Fast Track, and RMAT designations, while the European Medicines Agency has provided Orphan Medicinal Product designation and PRIME eligibility. Additionally, the U.K. Medicines and Healthcare products Regulatory Agency has included it in the Innovative Licensing and Access Pathway. These designations are expected to expedite the development and potential approval of the therapy, which aims to treat Fabry disease. Sangamo is preparing a Biologics License Application  submission for 2026, following positive results from the Phase 1/2 STAAR study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL8NJSLB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","SGMO","BK4139"],"gpt_icon":0},{"id":"2545847872","title":"Sangamo Therapeutics Inc - to Submit Bla in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2545847872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545847872?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:05","pubTimestamp":1750766700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABNQZ71:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4139","SGMO"],"gpt_icon":0},{"id":"2545284784","title":"Sangamo Therapeutics Inc - Isaralgagene Civaparvovec Shows Favorable Safety and Tolerability Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2545284784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545284784?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:05","pubTimestamp":1750766700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABNQZ71:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4139","SGMO"],"gpt_icon":0},{"id":"2545284735","title":"Sangamo Therapeutics Inc - STAAR Study Shows Positive Mean Annualized Egfr Slope at 52 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2545284735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545284735?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:05","pubTimestamp":1750766700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABNQZ71:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4556","SGMO"],"gpt_icon":0},{"id":"2545284254","title":"Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2545284254","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545284254?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:05","pubTimestamp":1750766700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABNQZ71:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMO","BK4556"],"gpt_icon":0},{"id":"2545540695","title":"The Best Stocks to Invest $1,000 in Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2545540695","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545540695?lang=en_us&edition=fundamental","pubTime":"2025-06-24 16:17","pubTimestamp":1750753020,"startTime":"0","endTime":"0","summary":"It's time to look at some names that have been flying under the radar.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/24/the-best-stocks-to-invest-1000-in-right-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4548","BK4524","LU1861559042.SGD","LU1720051017.SGD","BK4528","BK4551","SHOP","LU0390134368.USD","BK4139","LU1804176565.USD","BK4539","LU0823421416.USD","BK4116","CFLT","LU1720051108.HKD","BK4613","CRSP","LU2357305700.SGD","LU1861558580.USD","BK4585","BK4588","BK4611","BK4556","LU2265009873.SGD","LU1548497426.USD","BK4023","BK4566","LU0823421333.USD","BK4532"],"gpt_icon":0},{"id":"2545487315","title":"2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2545487315","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545487315?lang=en_us&edition=fundamental","pubTime":"2025-06-22 06:10","pubTimestamp":1750543800,"startTime":"0","endTime":"0","summary":"These biotech companies have several catalysts ahead -- and in the past have soared on good news.They both offer innovative candidates that could result in game-changing treatments for patients.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/21/2-biotech-stocks-to-buy-before-they-soar-84-and-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1861559042.SGD","BK4585","CRSP","LU1861558580.USD","BK4139","BK4588","BK4611","BK4556"],"gpt_icon":0},{"id":"2544129166","title":"Crispr Therapeutics AG (CRSP) Gets a Hold from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2544129166","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544129166?lang=en_us&edition=fundamental","pubTime":"2025-06-20 18:45","pubTimestamp":1750416348,"startTime":"0","endTime":"0","summary":"In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report). The c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-gets-a-hold-from-bernstein-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-gets-a-hold-from-bernstein-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRSP","BK4611","BK4556","BK4588","LU1861558580.USD","LU1861559042.SGD","BK4210","BK4139","BK4585","AG"],"gpt_icon":0},{"id":"2544499314","title":"Editas Medicine Is Great. Here's Why You Shouldn't Buy It.","url":"https://stock-news.laohu8.com/highlight/detail?id=2544499314","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544499314?lang=en_us&edition=fundamental","pubTime":"2025-06-17 22:07","pubTimestamp":1750169220,"startTime":"0","endTime":"0","summary":"The clinical-stage biotech is developing gene-editing CRISPR technology.The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine  is a promising clinical-stage company that has captured Wall Street's attention at the forefront of the gene-editing revolution with a unique approach to CRISPR technologies.On the other hand, Editas faces a long road ahead before delivering its first Food and Drug Administration  approved therapy and reaching its goal of transforming into a commercially sustainable biotech. The stock, with a market capitalization of $170 million, has also been extremely volatile, down 62% over the past year despite a sharp 32% rebound in the past month as of this writing.Here's why you should proceed with caution if you're thinking about buying shares of Editas Medicine for your portfolio.Image source: Getty Images.What does Editas Medicine do?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/17/editas-medicine-is-great-heres-why-you-shouldnt/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4556","LU1861558580.USD","BK4139","CRSP","BK4588","BK4585","EDIT","BK4611","LU1861559042.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}